The smoking habits of 82 patients with malignant-phase hypertension were compared with those of subjects in three control groups matched for age and sex. Sixtyseven (82%) of the patients with malignant-phase hypertension were smokers compared with 41 (50%) and 71 (43%) of the patients in two control' groups with non-malignant hypertension, and 43 people (52%) in a general population survey. The excess of smokers in the malignant-phase group was significant for men and women, together and separately, for cigarette smoking alone, and for all forms of smoking. There were no significant differences between the control groups. The chance of a hypertensive patient who smoked having the malignant phase was five times that of a hypertensive patient who did not. Twelve patients in the malignant-phase group had never smoked. All were alive three and a half years on average after presentation (range 11 months to seven years). Twenty-four (36%) of the smokers with malignant-phase hypertension died during the same period. The mortality rate was significantly higher among patients with renal failure, as was the prevalence of smoking. Eighteen patients with malignant-phase hypertension had a serum creatinine concentration higher than 250 stmol/l (2 8 mg/100 ml); 17 were smokers and one an ex-smoker. Eleven of these 18 patients died.
pathy of diabetes4 are said to be commoner among smokers, though the second claim is disputed.5 Malignant-phase hypertension is characterised by another form of haemorrhagic retinopathy,6 but, as far as we are aware, the smoking habits of patients with the condition have not been reported. We In none of the control groups were the smoking habits of the patients who were matched significantly different from those of the population from which they were derived.
Results
Proportions of smokers in each group-Sixty-seven (82"%) of the patients with malignant-phase hypertension were smokers compared with 41 (500o), 71 (43°O), and 43 (52%) in the three matched control groups B, C, and D, respectively. Differences between the malignantphase and control groups were significant for both sexes separately and together, for all forms of smoking combined, and for cigarette smoking alone. There were no significant differences between the three control groups nor was there a large difference between control groups and results of a national survey of smoking habits in 1975 performed by the Tobacco Research Council" (table I). The chance of a smoker having malignant hypertension was between three and five times that of a non-smoker. This was assessed by Odd's ratio, comparing data on patients with malignant-phase hypertension with those from different control groups (table II) . Because smoking varies with social class"' it was important to ensure that classes 4 and 5 (Registrar General's classification) were not overrepresented among patients with malignant hypertension since this would tend to raise the proportion of smokers within the group. No influence of this sort was apparent. Social classes 4 and 5 contributed 13 (160%) of the patients in each of groups A and B.
Mortality-Malignant-phase hypertension is characterised by renal failure and high mortality as well as retinopathy. Among patients with malignant-phase hypertension, smokers seem to fare worse in both respects: of the 12 patients in this group who had never smoked, all were alive 3-42 years on average after presentation (range 11 months to seven years). Among the 67 smokers, on the other hand, 24 deaths (36o> mortality) occurred within a mean of 3-97 years, a significantly higher mortality (P<0 01, Fisher's exact test). Although the smokers had a marginally lower average blood pressure at presentation (228/146 compared with 238/151 mm Hg in non-smokers), a factor favouring survival, their slightly higher average age (44 4 compared with 38 7 years) and longer follow-up would have had the opposite effect. Even in combination, however, these factors are insufficient to account for the excess mortality among patients with malignant-phase hypertension who smoke. No such difference was apparent in the patients in group B: one of the smokers (2 4'o) and none of those who had never smoked died during the same period.
Renal failure-Fifty-two (63"o) of the patients in the malignant phase had raised serum creatinine concentrations (upper limit of normal 115 .umol/l (1 3 mg/100 ml)). The average serum creatinine concentration was 106 smol/1 (1 2 mg/100 ml) for the 12 malignantphase patients who had never smoked. The concentration in the 67 smokers in the group was 224 smol/l (25 mg/100 ml) (t=2 28; P<0 05). Eighteen patients (220o, of the total) had creatinine concentrations of over 250 :smol/l (28 mg/100 ml), and of these, 17 were smokers. The one exception was an ex-smoker. Eleven of these 18 patients (61°o) died. By comparison only seven (9 o) of the patients in group B had abnormal renal function.
Thus smoking was commoner among patients with malignant-phase hypertension; smokers with malignant-phase hypertension were more likely to have renal failure; those with renal failure were more likely to die; and those who died were more likely to have been smokers.
Discussion
Several potential sources of error and bias exist in a retrospective analysis of this sort. Smoking varies year by year and with age, sex, and social class.' 1" Our data for groups A and B, however, were contemporary; age and sex were matched in all groups and there was no important difference in social class between groups A and B. The smoking habits of patients in the There are three main explanations for an association between smoking and disease. A disease may encourage patients to smoke; smoking may predispose to a disease; or a third agent may, separately, predispose to a disease and encourage patients to smoke. These issues have been extensively debated, and most investigators now agree that smoking predisposes to, causes, or accelerates several important vascular diseases.' 216 The same questions arise here: does excess smoking predispose to malignant hypertension; does the disease encourage patients to smoke; or is there a third agent encouraging both ? We know of no evidence favouring the second or third possibility. If the second were true, more than a quarter of our patients would have had to begin smoking for the first time in the usually brief interval between the abrupt onset of malignant-phase hypertension and the recording of smoking habits. This was not seen in the patients with non-malignant hypertension admitted to the same ward and given similar treatment.
We think it more likely that smoking predisposes to the development of the malignant phase in a patient who is already hypertensive. This may explain the higher mortality from hypertension among smokers.2 Clearly smoking is not the only cause of malignant-phase hypertension; some of our patients had never smoked. Nor is it likely to be the primary cause. Most workers, including ourselves, agree that increased In the group with malignant hypertension mortality was higher among smokers. Increased mortality would be expected in any group containing a high proportion of smokers, but a 36O, mortality rate over four years in a group with a mean presenting age of 44 years is more than could be expected from this alone. The mortality rate among smokers with nonmalignant hypertension was only 2-40o during the same period. Smoking was also related to renal failure, and, as would be expected,6 renal failure was related to a fatal outcome. This raises the possibility that smoking predisposes to malignant hypertension and to a fatal outcome from renal failure. The two effects are not necessarily independent. The characteristic vascular abnormality of malignant-phase hypertension in the kidney is the same as that in other susceptible organs. The intravascular coagulation in the malignant phase, which may be produced by smoking, is particularly pronounced within the kidney.
People who stop smoking are less likely to develop vascular disease. Those with vascular disease decrease the chance of further complication when they stop smoking.' 2 16 On the evidence presented here we believe that patients with hypertension should be advised to stop smoking. At worst their chance of developing cancer and several important vascular diseases will be reduced when they stop; at best there may be additional protection from malignant-phase hypertension, a particularly lethal form of vascular disease.
The present study was prompted by a clinical impression of a higher incidence of cigarette smoking among patients with malignant-phase hypertension when compared with those with non-malignant hypertension, and a report of an association between cigarette smoking and diabetic retinopathy.4 We therefore analysed the smoking habits of all patients with malignant-phase hypertension admitted to this hospital over the past six years and compared them with 92 consecutive patients with non-malignant hypertension who were attending the blood-pressure clinic at this hospital. A similar and parallel study was conducted by colleagues in Glasgow.5
Patients and methods
We obtained the case records of 48 consecutive cases of malignantphase hypertension admitted to this hospital during 1972-8. The criterion for inclusion in this group was the presence of bilateral retinal haemorrhages or exudates with or without papilloedema. As this analysis was conducted retrospectively by examining the notes we could include only cases whose ICD diagnostic code was 400 (malignant or accelerated hypertension). Notes were checked to ensure that the retinal changes had been recorded. Patients with renal disease were not excluded; four patients had chronic pyelonephritis and one congenital hypoplastic kidneys. One patient had current phaeochromocytoma; the remainder had essential hypertension. Of the 48 patients, 16 had a serum urea concentration above 10 mmol/l (60 mg/100 ml). The series included six diabetics (fasting blood glucose ->6 5 mmol/l (->117 mg/100 ml)), of whom four smoked;
